Determinants of Frontline Tyrosine Kinase Inhibitor Choice for Patients with Chronic-Phase Chronic Myeloid Leukemia: A Study from the Registro Italiano LMC and Campus CML

A total of 1967 patients with chronic-phase chronic myeloid leukemia diagnosed between 2012 and 2019 at 36 centers throughout Italy were retrospectively evaluated; 1089 patients received imatinib and 878 patients received a second-generation tyrosine kinase inhibitor.